文献速递认知障碍与痴呆

[18F]AV-1451 tau PET显像与典型及非典型阿尔茨海默病的皮层萎缩和症状关联

Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease.
PubMed 文献 · JAMA Neurol · 2017-01-01

结果显示临床表型与[18F]AV-1451信号区域分布相符,且各患者68个皮层感兴趣区内皮层萎缩程度与[18F]AV-1451结合量强相关,而与[11C]PiB结合无关。

要点

  • [18F]AV-1451 tau PET信号分布与阿尔茨海默病临床表型一致。
  • 皮层萎缩程度与[18F]AV-1451结合量强相关,与[11C]PiB结合无关。
  • tau PET有望成为连接分子病理与临床显著神经变性的关键生物标志物。

核心结论

  • [18F]AV-1451信号分布是临床症状和神经变性的有效在体标志物。
  • tau PET有望作为连接特定分子神经病理与临床显著神经变性的关键生物标志物。

研究设计与样本

  • 观察性病例系列,2012年7月1日至2015年7月30日在神经退行性疾病门诊转诊中心开展。
  • 纳入6例患者:3例典型遗忘型阿尔茨海默病和3例非典型变异型(后皮层萎缩、logopenic变异型原发性进行性失语、皮质基底节综合征)。
  • 患者接受[18F]AV-1451 PET测tau负荷、[11C]PiB PET测淀粉样负荷及结构MRI测皮层厚度。

主要发现

  • 全部6例患者(3女3男,平均年龄61.8岁)的临床表型与[18F]AV-1451信号区域分布相关。
  • 每例患者68个皮层感兴趣区内,皮层萎缩程度与[18F]AV-1451结合量强相关(3例遗忘型:r=-0.82,P<.001;r=-0.70,P<.001;r=-0.58,P<.001;3例非遗忘型:r=-0.51,P<.001;r=-0.63,P<.001;r=-0.70,P<.001)。
  • 皮层萎缩与[11C]PiB结合无相关性。

临床怎么用

  • [18F]AV-1451 tau PET可用于在体定位和量化过度磷酸化tau,辅助解释阿尔茨海默病临床表型与神经变性模式。
  • tau PET有望作为生物标志物推动疾病修饰治疗的研发。

局限性

  • 样本量仅6例患者,属观察性病例系列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Previous postmortem studies have long demonstrated that neurofibrillary tangles made of hyperphosphorylated tau proteins are closely associated with Alzheimer disease clinical phenotype and neurodegeneration pattern. Validating these associations in vivo will lead to new diagnostic tools for Alzheimer disease and better understanding of its neurobiology. OBJECTIVE: To examine whether topographical distribution and severity of hyperphosphorylated tau pathologic findings measured by fluorine 18-labeled AV-1451 ([18F]AV-1451) positron emission tomographic (PET) imaging are linked with clinical phenotype and cortical atrophy in patients with Alzheimer disease. DESIGN, SETTING, AND PARTICIPANTS: This observational case series, conducted from July 1, 2012, to July 30, 2015, in an outpatient referral center for patients with neurodegenerative diseases, included 6 patients: 3 with typical amnesic Alzheimer disease and 3 with atypical variants (posterior cortical atrophy, logopenic variant primary progressive aphasia, and corticobasal syndrome). Patients underwent [18F]AV-1451 PET imaging to measure tau burden, carbon 11-labeled Pittsburgh Compound B ([11C]PiB) PET imaging to measure amyloid burden, and structural magnetic resonance imaging to measure cortical thickness. Seventy-seven age-matched controls with normal cognitive function also underwent structural magnetic resonance imaging but not tau or amyloid PET imaging. MAIN OUTCOMES AND MEASURES: Tau burden, amyloid burden, and cortical thickness. RESULTS: In all 6 patients (3 women and 3 men; mean age 61.8 years), the underlying clinical phenotype was associated with the regional distribution of the [18F]AV-1451 signal. Furthermore, within 68 cortical regions of interest measured from each patient, the magnitude of cortical atrophy was strongly correlated with the magnitude of [18F]AV-1451 binding (3 patients with amnesic Alzheimer disease, r = -0.82; P < .001; r = -0.70; P < .001; r = -0.58; P < .001; and 3 patients with nonamnesic Alzheimer disease, r = -0.51; P < .001; r = -0.63; P < .001; r = -0.70; P < .001), but not of [11C]PiB binding. CONCLUSIONS AND RELEVANCE: These findings provide further in vivo evidence that distribution of the [18F]AV-1451 signal as seen on results of PET imaging is a valid marker of clinical symptoms and neurodegeneration. By localizing and quantifying hyperphosphorylated tau in vivo, results of tau PET imaging will likely serve as a key biomarker that links a specific type of molecular Alzheimer disease neuropathologic condition with clinically significant neurodegeneration, which will likely catalyze additional efforts to develop disease-modifying therapeutics.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Xia C, Makaretz SJ, Caso C, et al. Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease. JAMA Neurol. 2017. PMID: 28241163. doi:10.1001/jamaneurol.2016.5755

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。